Adana A.M. Llanos, PhD, MPH, discusses key research on the social and biological factors that influence disparities in breast cancer, how these factors work in tandem to affect patient outcomes, and how this knowledge can be deployed in the real world.

Although genetic and biologic factors play a key role in outcomes for patients with breast cancer, social and structural determinants also have a place in the equation. Addressing these existing genetic factors and social determinants, thereby improving prevention and detection, can help reduce disparities in metastatic breast cancer, where Black women historically present more frequently at advanced stages and have worse outcomes, according to Adana A.M. Llanos, PhD, MPH.

In a presentation during the 2022 ASCO Annual Meeting, Llanos highlighted how understanding the genetic and etiological aspects of breast cancer can help inform prevention and screening techniques. The next challenge for physicians will be implementing these ideas into community practice to better serve underrepresented patient populations.1

Focusing on all of the different time points throughout [the cancer care] continuum will be a critical aspect of achieving more health equity and more equitable outcomes, Llanos said. This is a major goal throughout my long-term research interests.

In an interview with OncLive, Llanos discussed other key research on the social and biological factors that influence disparities in breast cancer, how these factors work in tandem to affect patient outcomes, and how this knowledge can be deployed in the real world. She is an associate professor of Epidemiology at the Mailman School of Public Health at Columbia University and an adjunct associate professor at Rutgers School of Public Health.

Llanos: My talk was part of a discussion involving 2 selected abstracts. The session included abstracts that focused on some of the racial, ethnic, and regional disparities in metastatic breast cancer.

The lead author for the first abstract is Sachi Singhal, MD, [who explored racial and regional disparities in metastatic breast cancer].2 The second abstract focused on the variation of genetic mutations, specifically pathogenic variants in breast cancer predisposition genes, and how they're related to triple-negative breast cancer [TNBC].3 That abstract was presented by Michael J. Hall, MD, MS.

In my talk, I provided an overview of some of the existing racial and ethnic disparities that we see in breast cancer in the United States, highlighting stage distribution and focusing on the fact that the distribution of tumor stage varies by race and ethnicity. We see high rates [of advanced stages of disease] among Black women. Moreover, I talked about some of the factors related to this disparity in advanced stage diagnosis by race.

I also presented the distribution of tumor subtypes, focusing on TNBC, which tend to be among the most aggressive forms of breast cancer. We see that the incidence of TNBC is substantially higher in Black women. [Our goal is to gain a greater] understanding of how some of the racial, ethnic, and ancestral [factors of breast cancer intersect and interact with] genetics and social determinants of health to contribute to these disparities and how they impact poor outcomes among some patient groups.

This session highlighted some of the facts that clinicians already know. The abstracts [by Drs Singhal and Hall] got at the biology [of breast cancer] and the social/structural determinants that could be related and working together to impact outcomes.

Im an epidemiologist, and Im interested in studying social and biological factors that contribute to disparities. One of the takeaways in my talk was how we can address breast cancer disparities at multiple phases in the cancer control continuum. This includes looking at etiology and biology, which is more focused on genetics and ancestry. These are things that we cannot change but understanding them better will give us a good sense of ways that we can address disparities.

Looking at prevention, we talk a lot about precision medicine and treatment. However, maybe we should be talking more about precision prevention, [which includes] detection and diagnosis. There are disparities [in these spaces], and [it is important to consider] how we can address those disparities.

Guideline-concordant treatment was not a major focus of my talk but understanding the genetics behind some of these disparities will contribute to improving the treatment options and guideline-concordant treatment for patients with breast cancer. Lastly, public health is important. [We need to learn] how to deploy all this knowledge to have a broader impact on patients and communities.

[Considering] the emerging data and studies around the genetics of TNBC, one of the limitations of a lot of the existing and past research is the historical underrepresentation of racial and ethnic minority groups, especially those of African ancestry. As new studies and larger studies are initiated, it is critical to have broad representation of diverse ancestral backgrounds to [allow investigators] to get a sense of some of the genetic and etiological differences, why they exist, and how [these factors] can impact treatment.

As important as biology and genetics are, we need to consider the social determinants and structural determinants across the entire cancer care continuum, not just for breast cancer, but for all cancers.

Read more from the original source:
Social Determinants and Genetics Work in Tandem to Drive Disparities in Breast Cancer Care - OncLive

How can the biology of a crop be manipulated for greater profits in this fast-growing market through breeding?

Since early farmers began collecting seeds for propagation, they focused on varieties that performed best in unpredictable field conditions, not in highly controlled environments. Specifically, crop plants exude up to 40% photosynthate into the soil to "feed" beneficial microbes and allocate additional resources to produce secondary products to protect against pests and diseases.

Unlocking the full potential of seed for precisely controlled environments, where every day is a good day, will allow breeders to focus on plant characteristics that improve when grown indoors and downplay problems that would be of great concern for outdoor production. As we control the environment more, we can engineer crops with traits to delight the consumer and improve the supply chain.

Marc Oshima, co-founder of AeroFarms, says, "For vertical farms, breeders can focus on qualities of primary importance to consumers: flavor, aroma, texture, and other quality-related attributes. It's also important to have plants that are architecturally efficient so that they can be easily maintained and harvested in our unique environment."

The biggest breeding goals for field-grown fruits and vegetables are disease resistance. Breeders are spinning on a treadmill to stay ahead of the next disease in the field. It's not simply a matter of swapping disease-resistant genes for genes that confer good flavor, but CEA allows breeders to stay ahead of the next potentially devastating disease outdoors. Some diseases, such as powdery mildew, are possible indoors but can often be controlled by management practices.

Source: http://www.bioeconomia.info.

The rest is here:
The power of genetics to unleash the potential of indoor farming - Vertical Farm Daily

Mortality has always been on Perry Jones mind, much more so than your average 20-something. Shes dealt with a number of challenging health conditions since her teens, so when her mother urged her to be screened for the BRCA1 variant and BRCA2 variant gene a couple of years ago (both of which indicate a high risk of breast and ovarian cancer) she didnt exactly jump at the chance.

Jones, who has type 1 diabetes, coeliac disease and spinal development issues, speaks about her dealings with the health system in the world-weary way of someone whos been in and out of waiting rooms her whole life.

Ive got the whole wazoo. So a part of me was like, Whats the likelihood that Im going to have another thing? Itll be fine. Theres no point.

But Jones mother insisted. After all, shed been diagnosed with breast cancer at the age of 40. Mum said its better to know than not to know. And if we know, then we can warn others in our family and we can look into better treatment methods for ourselves in future.

Eventually, Jones agreed to take the saliva test. And then I forgot about it. So when I did get that phone call, to tell me I had the (BRCA1) gene, I was like, Oh, youve got to be kidding me.

Jones results have the potential to save her life, but they have also irrevocably informed the way she views and plans for her future, regardless of whether she ever receives an eventual diagnosis. As technological advancements and decreasing costs make testing accessible to broader swathes of the population, what does it mean to know the risk embedded within our DNA?

Last month, Monash University launched DNA Screen, offering 10,000 people aged 18 to 40 secure, free DNA testing to identify risk of cancer and heart disease that can be prevented or treated early.

The study is a chance to gauge the public appetite for preventive genetic testing (as opposed to the current status quo of clinical criteria-based testing) and could help Australia become the first country to offer preventive DNA screening through a public healthcare system.

The appetite from people in this age bracket was overwhelming. The DNA Screen team initially aimed to contact young people across social media to spread the word. Instead, without social media promotion, the website reached their target of registering 10,000 people to do the at-home saliva tests in 24 hours.

The interest is enormous, says Jane Tiller, co-lead of the project and ethical, legal and social adviser for Public Health Genomics at Monash.

DNA Screen, which is partly funded by the federal government, is attempting to pilot and demonstrate the value of population-level screening in an effort to provide greater access to genomics for everyone, similar to the mass bowel and breast cancer screening the government already funds for older Australians. Historically, the costs of genetic testing have been prohibitive, which meant it was only available to people with a family or personal history of disease, but up to 90% of people at high risk are not identified by current family history-based testing.

Although there are many genes that could be studied, the researchers picked 10 gene variants because the conditions they can lead to are medically actionable and there are already preventive measures for them hereditary ovarian and breast cancer, Lynch syndrome and familial hypercholesterolaemia (which increases the likelihood of having coronary heart disease at a younger age).

Those found to be at high risk after DNA testing expected to be about one in 75 will have their situation explained by experts and be offered genetic counselling and prevention measures, such as regular scans and check-ups. Given the stats, roughly 130 people from the study are likely to be found to be high risk. But what does it mean to scale up genetic screening and introduce mass preventive testing into any health system?

Bringing genetic screening into public health has huge promise if we use it wisely, says Prof Ainsley Newson, professor of bioethics at the University of Sydney. But there are questions to consider. For health problems where there isnt a good way to find and diagnose people, can genetics help? If a gene test exists, is it reliable in diverse populations? Does it only detect what we want to know, and nothing else? Is the health system ready to support those who are identified as at higher risk? Is there something people can do with the information it generates, and is there evidence that they will take that action?

Tiller and her co-leads have considered those same questions. If we were to test the whole of Australia tomorrow that would likely identify a number of people that may start to create a strain on a service that may not be resourced to deal with that many people, she says.

But we cant pretend that just not screening is the answer to protect the resources of the health system, because people who are at risk and develop cancer and need care will eventually need that system. And its far better to front-load your preventive care and keep people healthy and well.

The response for the DNA Screen study indicates there is widespread demand for this information beyond people such as Jones with family histories. It is powerful and heavy knowledge. Who seeks this information out?

Its a mix of people who are very big on preventive health who see that connection between finding out information now and being able to do something about it and then people who are just curious, says Tiller. Weve seen a huge increase in ancestry testing in recent years and people being interested to see whats in their genes.

Therell always be people who say, Im not interested in that. I would be too worried. I wouldnt want to know. And thats completely a personal choice.

Sign up to Guardian Australia's Morning Mail

Our Australian morning briefing email breaks down the key national and international stories of the day and why they matter

Communicating what the results could mean is a vital first step. Tiller says they want to ensure people understand that finding a gene is not a diagnosis of a condition and that not finding a gene doesnt mean they wont ever get cancer or heart disease.

This isnt about fear-mongering we really want to say to people, If you would like to know about this, this can empower you to take preventive steps for your own health.

So what does it mean for a young person to take on that information, to shape their hypothetical future with knowledge that wasnt available to any of us just a few years ago?

For the one in 75 people who are found to be high risk, it can of course be distressing, says Tiller. Theres a lot of support thats required in the initial stages of giving people that information, giving them space to perhaps feel some distress, to grieve over what that might mean for them and to support them through the next steps of decision-making.

Every person reacts differently to what their results could mean for them and their family. For Jones, her results have meant a cascading series of future choices and consequences, all of which are hypothetical at this stage.

Protective surgery such as a double mastectomy was initially suggested, which Jones has thus far resisted. She was also told that she should consider having her ovaries removed as soon as possible. So that changed my view of my timeline for starting a family.

Jones is also acutely aware she could pass the gene on to future children. Shes single and is studying a bachelor of design that she loves. Shed like to travel after graduation, maybe land an internship, meet someone nice.

But concurrently, at the age of 28, she has already weighed up scenarios such as freezing her eggs (shes opted not to thus far); considered what shed do if an embryo tested positive for the variant (she would abort), considered the financial implications of IVF (shed rather conceive naturally, especially given she needs to save a deposit for a house); weighed up how shell tell a future partner about her genetic risk (shed be upfront); and worried about menopause and what it means for removing her ovaries (Im actually more worried about that than the cancer at the moment to be honest). Those possibilities are a lot to deal with, she says. Shes banking on her future self, future and more mature Perry, to be able to handle them.

The knowledge she carries with her doesnt keep me up every night, but its definitely something ticking away in the back of my mind.

But despite all these considerations, Jones is grateful for the opportunity to be tested.

Having the test gave me a sense of control, even if I cant control whether or not I develop cancer. Im in control of knowing about it. I know the risks and I know what steps I can take to capture it as soon as possible if it develops.

Two years on from receiving her results, Jones is philosophical about living with what she knows. Shes much more vigilant and shes made peace with having to endure extra tests.

She also reminds herself that theres a chance that she may never be diagnosed. I guess I just accept that its part and parcel of the body that allows me to live. So whatever it comes with, Im just going to have to deal with. And as much as I dont like carrying these genes, its better to be alive and have them than not at all. So Im still thankful for this meat cage that contains my consciousness.

Excerpt from:
Ticking away in the back of my mind: what does it mean to know the risk embedded in your DNA? - The Guardian

The CrispResist, NoLice and GenoLice research team

Results from the research could help improve the ability of whole stocks of farmed fish and shellfish to avoid and fight off infectious diseases and parasitesNofima

Disease and parasitism cause major welfare, environmental and economic concerns for global aquaculture. A broad team of scientists has been assembled to examine the status and potential of technologies that exploit genetic variation in host resistance to tackle this problem.

In environments that contain high densities of animals or plants there is a high risk of contracting, propagating and spreading infectious disease. Diseases affecting fish and shellfish can lead to 100 percent mortality, necessitate complete destocking and/or severely affect fish welfare. Disease prevention and treatment are necessary, but current options are often costly, ineffective and can negatively impact animal welfare, local ecosystems and product quality. For example, biosecurity is particularly challenging when animals are farmed in an open water system, and logistical difficulties in handling makes it challenging to vaccinate and treat individual animals.

But is there a way that we could improve the ability of whole stocks of farmed fish and shellfish to avoid and fight off infectious diseases and parasites? To answer this question we need to study the improvement of host disease resistance which can be defined as the hosts ability to reduce pathogen invasion (ie limiting pathogen entry into target tissues and replication).

The team is reviewing genetic technologies that can be used to determine the mechanisms underlying host resistance to pathogens and parasitesNicholas Robinson, Nofima

In a new paper published in the latest issue of Reviews in Aquaculture we argue that there is an urgent need to improve understanding of the genetic mechanisms involved, leading to the development of tools that can be applied to boost host resistance and reduce the disease burden. Together with other experts on fish and shellfish breeding, genetics, genomics, proteomics, disease biology, immunology, feed technology, epidemiology, biochemistry, welfare, vaccine discovery, behaviour and gene editing we draw on two pressing global disease problems as case studies sea lice infestations in salmonids and white spot syndrome in shrimp.

We review how the latest genetic technologies can be capitalised upon to determine the mechanisms underlying host resistance to pathogens and parasites, and how the derived knowledge could be applied in ethical and efficient ways to boost disease resistance using selective breeding, gene editing, and/or with targeted feed treatments and vaccines.

Substantial research programmes are underway that aim to produce new knowledge that could be applied for boosting host resistance to eliminate or severely reduce infections by, for instance, sea lice in salmon and WSSV in shrimp.

These projects are utilising a suite of technologies that have been enabled by ultra-high throughput sequencing, such as single nuclei and spatial transcriptomics and single nucleotide polymorphism genome-wide association studies. Newly developed methodologies like in-vivo or in-vitro gene editing and functional testing hold great promise for helping to find and test genetic mechanisms affecting host resistance. These projects are also exploring the possibility of using genomic selection and gene editing with CRISPR-Cas9 to create host populations that will resist these diseases.

The implementation of these technologies needs to be carefully considered. Practical methods that will allow easy adoption, implementation and dissemination by aquaculture sectors are needed. Population genetic variability needs to be maintained, inbreeding limited and possibilities for the genetic improvement of other important traits must be ensured. Ethical concerns, particularly about the use of gene editing, need to be openly discussed and debated in public arenas, and thorough testing and safeguards (eg sterilisation) are needed to ensure that there are no negative consequences for the wild populations of these species or for the broader ecosystem.

The application of new genomic technologies and methodologies is expected to generate knowledge about genes that trigger a more effective immune response in some species or lines; the effect that could be realised by editing these genes in more susceptible species or lines; potential lice attractants, repellents and assays; and the extent of additive genetic variation affecting the production and release of important immune factors and semiochemicals.

Results from the research could help develop of feed additives, gene edits, new vaccines and enhance genomic breeding value estimation that promotes host resistanceNofima

Such knowledge could lead to the development of feed additives, gene edits, new vaccines and the enhancement of genomic breeding value estimation to promote host resistance. The epidemiological implications of these applications on the infectivity and virulence of aquatic diseases needs to be explored, and routines need to be devised to enhance the suppression of disease in the general aquaculture environment.

Such projects are ambitious in that it is hypothesised that specific semiochemical or immune pathways play major roles in differentiating disease-resistant from disease-susceptible hosts and that these differences are measurable, have a strong genetic basis, have implications for the epidemiology of infection and that genomic selection and/or gene editing approaches can be effectively and sustainably applied to reduce or eliminate the effect of disease on the host without counter-evolutionary responses by the infectious agent taking effect.

The long-term suppression of disease will only be realised through a collaborative and coordinated multi-disciplinary effort involving scientists working closely with the aquaculture industry and governments.

Success applying these genetic technologies to combat infectious disease has the potential to transform global aquaculture by greatly improving animal welfare and the sustainability of production.

Such efforts are likely to significantly advance our understanding of host-parasite and host-disease interactions and mechanisms affecting resistance to disease and should result in significant economic impacts for aquaculture sectors, benefit the welfare of production animals and create ecosystem benefits for natural populations of these species.

Application of genetic technologies and approaches has potential to improve fundamental knowledge of mechanisms affecting genetic resistance and provide effective pathways for implementation that could lead to more resistant aquaculture stocks. Large collaborative research efforts provide the best chance of achieving such goals. Success applying these genetic technologies to combat infectious disease has the potential to transform global aquaculture by greatly improving animal welfare and the sustainability of production.

Dr Robinson is also South-East Asia-Pacific contact at Nofima and Melbourne Enterprise Fellow in Aquaculture with the University of Melbourne. He has worked for 18 years with Nofima, focusing on the application of genomic technologies for the genetic improvement of aquatic species.

Read more:
How are genetic technologies being applied to combat infectious diseases in aquaculture? - The Fish Site

Hyderabad: CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad has been researching to understand the genetic causes of male infertility for the last two decades. As per the study, 38 per cent of males with infertility have specific regions missing or abnormalities in their chromosomes or mutations in their mitochondrial and autosomal genes.

CCMB's new multi-institutional study focuses on the cause of infertility in the rest of the cases, which constitutes the majority of infertility-affected men. The researchers have identified eight novel genes that were defective in these men in India. The study has been recently published online in the journal Human Molecular Genetics.

Dr Sudhakar Digumarthi, the lead author of the study, who was a Ph D student of CCMB and presently a scientist at ICMR-National Institute for Research in Reproductive and Child Health in Mumbai, said, "We first sequenced all the essential regions of all genes (around 30,000 of them) using next generation sequencing in 47 well-characterised infertile men. We then validated the identified genetic changes in about 1,500 infertile men from different parts of India."

Dr Thangaraj, lead investigator of this study and presently Director of the DBT-Centre for DNA Fingerprinting and Diagnostics, Hyderabad said, "We identified a total of eight genes (BRDT, CETN1, CATSPERD, GMCL1, SPATA6, TSSK4, TSKS and ZNF318), that were not known earlier for their role in human male fertility".

He further said that they have identified variations (mutations) in these genes that cause impaired sperm production leading to male infertility. The researchers have characterised a mutation in one of the eight genes, Centrin 1 (CETN1), to understand how the mutation affects sperm production. They demonstrated the impact of CETN1 mutation in cellular models and found that the mutation arrests cell division, causing insufficient sperm production.

This study should be a reminder to the society that half of infertility cases are due to problems in men. And many of them are due to genes that come from the parents, often mothers, of these men. It is wrong to assume a couple cannot bear children because of only the woman's fertility," remarked Dr Thangaraj.

Dr Vinay Kumar Nandicoori, Director, CCMB said, "The genetic causes established in this study can be used as potential diagnostic markers for male infertility and development of improved management strategies for male infertility".

Go here to see the original:
CCMB zeroes in on major genetic causes of male infertility - The Hans India

NEW YORK Illumina said this week that it has opened its first manufacturing site in China. The Shanghai-based facility will initially produce 16 clinical sequencing reagents. In a statement, the firm said it plans to "achieve complete localized production for its gene sequencing instruments and consumables within the next five years."

Interpace Biosciences this week announced the closing of the sale of its Pharma Services business to Flagship Biosciences for an undisclosed amount. Parsippany, New Jersey-based Interpace will use the proceeds of the transaction for working capital requirements and investments to help drive the growth of its molecular diagnostics business. The company said the disposition of its pharma services business is expected to improve operating cash flow by nearly $5 million annually.

The American Society of Human Genetics said this week that the Illumina Corporate Foundation has awarded it a one-year, $175,000 grant to support the ASHG learning center.

The web portal offers scientists access to professional education videos, webinars, workshops, and other content. ASHG said it would use the grant to implement closed captioning across its live and on-demand content. Other details were not disclosed.

Genetic Signatures this week reported fiscal year 2022 revenues of A$35.4 million, a 25 percent increase from A$28.3 million in FY 2021. The growth was driven by demand for the firm's EasyScreen SARS-CoV-2 Detection Kit, although the company said in a statement that demand for other non-COVID-19 tests has increased. The company's net income for the full year was A$3.3 million, or A$2.11 per share, compared to A$1.8 million, or A$1.23 per share, in the previous year. The Australian firm had A$36.9 million in cash and cash equivalents at the end of the fiscal year.

OpGen has been granted a 180-day extension from the Listing Qualifications Department of Nasdaq to regain compliance with the exchange's minimum bid price requirement. If at any time until Feb. 27, 2023, the bid price for OpGen's common stock closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the firm will regain compliance with the rule. The firm's share price hasn't closed at $1 or higher since mid-January.

Ochsner Health this week became the first healthcare system to incorporate Epic Systems' Orders and Results Anywhere integration with its genomic module. Physicians at New Orleans-based Ochsner, through the system's Precision Medicine Program, will now be able to order Tempus Health genomic tests for patients within the electronic health record system. Through the Epic EHRs, physicians can order genomic tests to identify actionable variants, in turn informing therapeutic decisions and clinical trial eligibility. In addition to Tempus, Epic has also partnered with Caris Life Sciences, Guardant Health, and Myriad Genetics to integrate biomarker testing into EHRs.

Guardant Health said this week that it has expanded its collaboration with Merck KGaA to further leverage the GuardantINFORM real-world evidence platform to help accelerate development efforts for the pharma firm's precision oncology pipeline. The expanded strategic collaboration will focus on therapy development for core cancer indications with significant unmet need.

Caris Life Sciences said this week that the Medical College of Wisconsin Cancer Center has joined its Precision Oncology Alliance, a growing network of leading cancer centers that collaborate to advance precision oncology and biomarker-driven research. MCW is the largest private research institution in Wisconsin, and its cancer center serves a distinct region that includes large, underserved populations of patients who experience significant disparities in cancer incidence and outcomes.

POA members gain access to a growing portfolio of biomarker-directed trials as well as Caris' CODEai, an industry-leading dataset with cancer treatment information and clinical outcomes data for over 275,000 patients.

The Malaysian Genomics Resource Centre Berhad said this week that it has signed a memorandum of understanding to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company. Under the MoU, the parties will explore the feasibility of Riyadh, Saudi Arabia-based Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell products, and exosome products. Ajlan will also identify commercial R&D opportunities for genome sequencing and analysis in the Middle East and North Africa region for areas such as agriculture, aquaculture, plantations, healthcare, and industrial biotechnology. In turn, Malaysian Genomics will analyze samples for genetic screening tests as well as provide Ajlan with genomic and bioinformatics expertise to bid for projects.

BioEcho Life Sciences, a Cologne, Germany-based biotech company specializing in nucleic acid extraction technology, has opened a US subsidiary in Boston. In a statement, BioEcho General Manager Lydia Willing noted that the company will provide an extensive portfolio of its products in the US and have the ability to work on specific customer needs around nucleic acid research.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.

Read more here:
In Brief This Week: Illumina, Interpace, Genetic Signatures, Guardant Health, More - GenomeWeb

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. ATOS, a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 14, 2022 at the Lotte New York Palace.

Mr. Guse will be available for one-on-one meetings. To request a meeting and to register for the conference, click below:

Annual Global Investor Conference

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

For more information, please visitwww.atossatherapeutics.com

Contact:

Atossa Therapeutics, Inc.Kyle Guse, General Counsel and Chief Financial Officerkyle.guse@atossainc.com

See the original post here:
Atossa Genetics (ATOS) Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Inves - Benzinga